Core Viewpoint - David Medical's stock has experienced fluctuations, with a recent decline despite a year-to-date increase, indicating potential volatility in the market [1][2]. Company Overview - David Medical, established on September 18, 1992, and listed on May 8, 2012, is located in Xiangshan, Ningbo, Zhejiang Province. The company specializes in the research, production, and sales of infant care equipment [2]. - The main revenue sources are: 51.93% from obstetric and pediatric care equipment, 45.88% from minimally invasive surgical instruments, and 2.18% from other products [2]. Stock Performance - Year-to-date, David Medical's stock price has increased by 31.03%. However, it has seen a decline of 3.17% over the last five trading days and 1.61% over the last 20 days. In contrast, the stock rose by 21.36% over the past 60 days [2]. - As of September 15, the stock price was reported at 14.64 CNY per share, with a market capitalization of 4.216 billion CNY [1]. Financial Performance - For the first half of 2025, David Medical reported a revenue of 251 million CNY, a year-on-year decrease of 5.48%. However, the net profit attributable to shareholders increased by 9.57% to 50.9767 million CNY [2]. Shareholder Information - As of August 29, the number of shareholders was 22,400, a decrease of 2.18% from the previous period. The average number of circulating shares per person increased by 2.23% to 6,417 shares [2]. - The company has distributed a total of 342 million CNY in dividends since its A-share listing, with 120 million CNY distributed in the last three years [3]. Institutional Holdings - As of June 30, 2025, among the top ten circulating shareholders, Jin Yuan Shun An Yuan Qi Ling Huo Pei Zhi Mixed Fund (004685) is the fourth largest with 900,000 shares, and Yuan Xin Yong Feng Ju You A (010469) is the fifth largest with 882,000 shares, both being new shareholders [3].

证券代码：300314 证券简称：戴维医疗 公告编号：2025-047 宁波戴维医疗器械股份有限公司 关于全资子公司医疗器械注册证变更的公告 宁波戴维医疗器械股份有限公司 董事会 2025年9月12日 一、医疗器械注册证变更具体情况 | | 一次性使用管型吻合 | 浙械注准 20152020237 | Ⅱ类 | 因材料变更等涉及的产 | | --- | --- | --- | --- | --- | | 序号 1 | 产品名称 器 | 注册证编号 | 注册分类 | 主要变更内容 品技术要求变更 | 二、对公司的影响及风险提示 上述医疗器械注册证"产品技术要求"的变更，符合公司的生产经营 实际，对公司发展具有积极影响，但尚无法预测上述变更事宜对公司未来 营业收入的影响，敬请广大投资者予以关注并注意投资风险。 特此公告。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 宁波戴维医疗器械股份有限公司（以下简称"公司"）全资子公司宁 波维尔凯迪医疗器械有限公司于近日取得由浙江省药品监督管理局颁发 的《中华人民共和国医疗器械变更注册（备案）文件》，公司产品一次性 使用管 ...

Core Viewpoint - Jin Hai Medical Technology (02225) experienced a significant stock price increase of over 41% in the afternoon trading session, with a cumulative rise exceeding 80% post-earnings announcement, despite reporting a substantial decline in revenue and an increase in shareholder losses [1] Financial Performance - The company reported a revenue of 14.529 million Singapore dollars, representing a year-on-year decrease of 43.98% [1] - Shareholder losses amounted to 10.253 million Singapore dollars, which is a year-on-year increase of 69.67% [1] Capital Raising and Use of Proceeds - The company announced a plan to issue 120 million new shares, which will represent approximately 2.27% of the enlarged share capital [1] - The net proceeds from this issuance are expected to be around 161 million Hong Kong dollars, intended for potential acquisitions in the healthcare sector, research and development expenses, and general working capital [1] Strategic Partnerships - On July 2, the company's wholly-owned subsidiary, Shanghai Jin Hai Medical Technology Co., Ltd., entered into a five-year cooperation framework agreement with Ningbo David Medical Instruments Co., Ltd. [1] - This agreement aims to collaborate on endoscope products in the international market, focusing on creating competitive high-end medical device solutions [1]

Group 1 - The company announced that its wholly-owned subsidiary, Ningbo Weierkaidi Medical Equipment Co., Ltd., has completed the registration procedures for changing its business scope due to business development needs [2] - The new business license has been approved and issued by the Ningbo Market Supervision Administration [2]

本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 宁波戴维医疗器械股份有限公司全资子公司宁波维尔凯迪医疗 器械有限公司（以下简称"维尔凯迪"）因业务发展需要，变更经营 范围，于近日完成了工商变更登记手续，并取得了由宁波市市场监督 管理局核准颁发的新的《营业执照》，具体内容如下： 统一社会信用代码：91330201750371740P 证券代码：300314 证券简称：戴维医疗 公告编号：2025-046 宁波戴维医疗器械股份有限公司 名称：宁波维尔凯迪医疗器械有限公司 关于全资子公司完成工商变更登记的公告 类型：有限责任公司（自然人投资或控股的法人独资） 2025年9月5日 住所：宁波市科技园区菁华路100号 法定代表人：陈再宏 注册资本：捌仟万元整 成立日期：2003年07月01日 经营范围：一般项目：第一类医疗器械销售；第一类医疗器械生 产；第二类医疗器械销售；电子元器件制造；技术服务、技术开发、 技术咨询、技术交流、技术转让、技术推广；货物进出口；技术进出 口（除依法须经批准的项目外，凭营业执照依法自主开展经营活动）。 许可项目：第二类医疗器械生产；第三类 ...

Group 1 - The core viewpoint of the article is that David Medical (300314.SZ) has received FDA certifications for some of its products, although none have been exported to the United States yet [1]

格隆汇9月3日丨戴维医疗(300314.SZ)在互动平台表示，公司产品目前暂未涉及机器人或机器自动化等 领域。 ...

Group 1 - Huazhong Securities has been approved to issue subordinate corporate bonds with a total face value of no more than 10 billion yuan [1] - Jinbei Automotive plans to invest 240 million yuan to establish an automotive industry investment fund focusing on electrification, intelligence, and low carbon [1] - Linyang Energy is expected to win a bid for a 244 million yuan metering equipment project from Southern Power Grid [1][2] Group 2 - Renfu Pharmaceutical's subsidiary has received drug registration certificates for two products, including a medication for acute hypotension [3][4] - Nanjing Steel plans to distribute a cash dividend of 0.1186 yuan per share [5][6] - Pairui Co. has signed a strategic cooperation agreement with Xi'an Power Electronics Research Institute to develop power devices [7][8] Group 3 - Haixing Electric is expected to win a bid for a 214 million yuan metering equipment project from Southern Power Grid [9][10] - Kuangda Technology is planning a change in control, leading to a continued suspension of its stock [11][12] - Samsung Medical is expected to win a bid for a 274 million yuan metering equipment project from Southern Power Grid [13][14] Group 4 - Jiukang Bio has obtained a medical device registration certificate for a specific diagnostic kit [15][16] - Hechuan Technology's minority shareholder plans to transfer a 13% stake in a subsidiary [17][18] - DiAo Micro has launched a new eUSB2 repeater product for various electronic applications [19][20] Group 5 - David Medical's electric surgical table registration application has been accepted [21][22] - Hangxin Technology plans to apply for a total of 280 million yuan in bank credit [23][24] - Liyuan Technology's non-independent director has resigned [25][26] Group 6 - Ningbo Construction's subsidiary has won a construction project bid worth 729 million yuan [27][28] - Huaren Pharmaceutical's subsidiary has received approval for a raw material drug [29][30] - Suwen Electric plans to distribute a cash dividend of 1 yuan per 10 shares [31][32] Group 7 - Solar Energy has received 1.692 billion yuan in renewable energy subsidies [33][34] - Wangli Security has obtained a patent for a new lock structure [35][36] - Zhejiang Energy's vice chairman has resigned due to age reasons [37][38] Group 8 - Beilu Pharmaceutical's subsidiary has passed GMP certification in Brazil [39][40] - Zhejiang Communications has a subsidiary that is expected to win a highway project bid [41][42] - Xinzhi Group has received a government subsidy of 11.1978 million yuan [43][44] Group 9 - Dong'an Power's engine sales in August increased by 3.44% year-on-year [45][46] - Baiyun Mountain's subsidiary has passed the consistency evaluation for two generic drugs [47][48] - Yipin Hong's subsidiary has received a drug registration certificate for a specific injection [49][50] Group 10 - Far East Holdings' subsidiary has won multiple contracts totaling 1.689 billion yuan [51][52] - Good Housekeeping's shareholder plans to reduce holdings by up to 3.5 million shares [53][54] - Guanghong Technology's shareholders have set a transfer price of 23.33 yuan per share [55][56] Group 11 - Keli Sensor plans to acquire 45% of Huahong Technology's shares for 122 million yuan [57][58] - Jianmin Group's furosemide oral solution has been approved for market launch [59][60] - Jinghua Laser's directors plan to reduce their holdings by up to 143,420 shares [61][62] Group 12 - Zhuyue Group is planning a share transfer that will change its controlling shareholder [63][64] - Terid has pre-bid for two projects totaling approximately 698 million yuan [65][66] - Zhonghuan Hailu is planning a change in control, leading to a continued suspension of its stock and convertible bonds [67][68] Group 13 - Great Wall Motors reported August sales of 115,600 vehicles, a year-on-year increase of 22.33% [69][70] - Guizhou Tire's controlling shareholder has committed not to reduce holdings for 12 months [71][72] - San Da Membrane's shareholder plans to reduce holdings by up to 1% of the company's shares [73][74] Group 14 - Chint Electric has decided to terminate the spin-off of its subsidiary for listing [75][76] - Jusaylong's shareholder plans to reduce holdings by up to 1% of the company's shares [77][78]

Group 1 - The company, David Medical, announced that it has recently obtained a "Notice of Acceptance" issued by the Zhejiang Provincial Drug Administration for its product, an electric surgical table [2] - The acceptance number for the product is: 20254028265 [2] - This development indicates a significant step in the regulatory process for the company's medical equipment [2]

Core Viewpoint - David Medical (300314.SZ) has recently obtained a "Notice of Acceptance" issued by the Zhejiang Provincial Drug Administration for its product, an electric surgical table [1] Group 1 - The company has received regulatory approval for a new medical device, indicating progress in its product development pipeline [1] - The electric surgical table is expected to enhance operational efficiency in surgical settings, potentially increasing the company's market competitiveness [1]